NCT06190704 (caIMR-HCM) is a clinical trial of caIMR in Coronary Cicrovascular Dysfunction, sponsored by Ya-Wei Xu.

Who is sponsoring NCT06190704?

NCT06190704 is sponsored by Ya-Wei Xu.

What drugs are being tested in NCT06190704?

Interventions in NCT06190704: caIMR.

What condition does NCT06190704 study?

NCT06190704 studies Coronary Cicrovascular Dysfunction, Hypertrophic Cardiomyopathy Patients.

Is NCT06190704 still recruiting?

NCT06190704 is currently completed. Last updated 8 January 2024.

Last reviewed 2024-01-08 · How we verify

NCT06190704: caIMR-HCM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prognostic Significance of CMD Assessed by IMR in HCM Patients

Completed Last updated 8 January 2024

What this trial tests

trial testing caIMR in Coronary Cicrovascular Dysfunction in 191 participants. Completed in 31 May 2023.

Timeline

13 September 2014

Primary endpoint
31 May 2023

31 May 2023

Quick facts

Lead sponsor	Ya-Wei Xu
Status	Completed
Study type	OBSERVATIONAL
Enrollment	191
Start date	13 September 2014
Primary completion	31 May 2023
Estimated completion	31 May 2023

Drugs / interventions tested

caIMR

Conditions studied

Coronary Cicrovascular Dysfunction — all drugs for Coronary Cicrovascular Dysfunction →
Hypertrophic Cardiomyopathy Patients — all drugs for Hypertrophic Cardiomyopathy Patients →

Sponsor

Ya-Wei Xu — full company profile →

Who can join

18 and older, any sex, with Coronary Cicrovascular Dysfunction or Hypertrophic Cardiomyopathy Patients. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The index of microcirculatory resistance (IMR) serves as an indicator of coronary microvascular dysfunction (CMD) with significant prognostic value in various clinical conditions. However, its impact on CMD in the hypertrophic cardiomyopathy (HCM), whether assessed invasively or non-invasively, is yet to be investigated. We assessed the prognostic importance of CMD using less invasive coronary angiography-derived IMR (caIMR) in HCM patients with nonobstructive epicardial coronary arteries.Patients with HCM who underwent invasive coronary angiography for suspected myocardial ischemia were included. Microvascular function was assessed using caIMR, and 460 coronary arteries were analyzed. CMD was identified with caIMR\>25U, in line with prior research, and the primary study endpoint was major adverse cardiac events (MACE).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Association of liver fibrosis-4 index with adverse outcomes in hypertrophic cardiomyopathy patients.
Abdu FA, Mareai RM, Xiang L, Galip J, et al · · 2024 · cited 5× · PMID 39049566 · DOI 10.1002/ehf2.14977

Verify or expand the search:

Other trials of caIMR

Trials testing the same drug.

NCT06945094 — A Multi-center, Real-World Clinical Trial of caIMR on Two Specific Kinds of Patients. · not yet recruiting
NCT06698432 — SHR Predicts CMD in Patients with CCS · completed

Other Ya-Wei Xu trials

Trials by the same sponsor.

NCT06690684 — Identification and Functional Study of Novel Biomarkers for Cardiovascular Diseases · enrolling by invitation
NCT05935436 — Cardiac Shock Wave Therapy for the Treatment of Myocardial Infarction With Non-obstructive Coronary Arteries · NA · unknown
NCT05354128 — Thrombolysis in STEMI Patients Compared With pPCI on Recanalization Time in the Context of the COVID-19 Outbreak. · NA · unknown
NCT06385782 — Exploring HRV in Antarctic Overwintering Members of Asia · completed
NCT03802929 — Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06190704 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ya-Wei Xu
Last refreshed: 8 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06190704.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing